Morbus Dupuytren – ein Fall für Manualtherapeuten?

Zusammenfassung

Die Behandlung eines Morbus Dupuytren ist kompliziert und delikat. In der Anfangsphase der Erkrankung nutzt die Manuelle Therapie als mechanische Therapie nur wenig und in späteren Phasen reagieren die starken Veränderungen der Faszien und Gelenkkapseln kaum noch auf manuelle Behandlungen. Daher sollten die Patienten in einem frühen Stadium physiotherapeutisch behandelt werden, um durch eine ganzheitliche Therapie den strukturellen Veränderungen entgegenzuwirken.

Abstract

Treatment of Dupuytren's contracture is complicated and delicate. In the initial stage of the contracture manual therapy as mechanical therapy is of little use and in later stages the extreme changes in the joint capsules hardly react to manual treatment at all. Therefore treatment with a comprehensive physiotherapy programme should best be initiated in the early stages in order to attempt to counteract the structural alterations.

Schlüsselwörter

Morbus Dupuytren - Physiotherapie

Key words

Duputren’s contracture - physiotherapy

Literatur

• 1 Balakrishnan C, Sugg K B, Huettner W et al. Dupuytren’s contracture following burn injury of the hand: A case report and review of literature.  Can J Plast Surg. 2008;  16 49-51
• 2 Bayat A, Walter J, Lambe H et al. Identification of a Novel Mitochondrial Mutation in Dupuytren’s Disease Using Multiplex DHPLC.  Plastic & Reconstructive Surgery. 2005;  115 134-141
• 3 Van den Berg F. Angewandte Physiologie. 3: Therapie, Training, Tests. Stuttgart: Thieme; 2007
• 4 Van den Berg F. Angewandte Physiologie. 4: Schmerzen verstehen und beeinflussen. Stuttgart: Thieme; 2008
• 5 Van den Berg F. Angewandte Physiologie. 6: Alterungsprozesse und das Alter verstehen. Stuttgart: Thieme; 2008
• 6 Van den Berg F. Angewandte Physiologie. 1: Das Bindegewebe des Bewegungsapparates verstehen und beeinflussen. Stuttgart: Thieme; 2010
• 7 Brickleys-Parsons D, Glimcher M J, Smith R J et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren’s disease.  J Bone Joint Surg Am. 1981;  63 787-797
• 8 Burge P, Hoy G, Regan P et al. Smoking, Alcohol and the Risk of Dupuytren’s contracture.  J Bone Joint Surg Br. 1997;  79-B 206-210
• 9 Gabbiani G. The Evolution of the Myofibroblast Concept: A Key Cell for Wound Healing and Fibrotic Diseases.  G Gerontol. 2004;  52 280-282
• 10 Hinz B, Phan S H, Thannickal V J et al. The Myofibroblast: One Function, Multiple Origins.  Am J Pathol. 2007;  170 1807-1816
• 11 Inagaki T, Katoh K, Takiya S et al. Relationship between Superoxide dismutase (SOD) and viral liver diseases.  Journal of Gastroenterology. 1992;  27 382-389
• 12 Karabulut A B, Sömmez E, Bayindir Y et al. A Comparison of Erythrocyte Superoxid Dismutase and Catalase Activity in Patients with Hepatitis C Infection.  Türk J Med Sci. 2002;  32 313-316
• 13 Kozma E M, Glowacki A, Olcyk K et al. Dermatan sulfate remodeling associated with advanced Dupuytren’s contracture.  Acta Biochemica Polonica. 2007;  54 821-830
• 14 Laukkanen M O, Leppanen P, Turunen P et al. EC-SOD gene therapy reduces paracetamol-induced liver damage in mice.  J Gene Med. 2001;  3 321-325
• 15 Lee S, Baytion M, Reinke D L et al. Dupuytren’s Contracture. 2010 http://www.emedicine.medscape.com/article/1238712-overview
• 16 Meek R MD, McLellan S, Crossan J F. Dupuytren’s disease: a model for the mechanism of fibrosis and its modulation by steroids.  J Bone Joint Surg. 1999;  81-B 732-738
• 17 Meek R M, McLellan S, Reilly J et al. The effect of steroids on Dupuytren’s disease: role of programmed cell death.  J Hand Surg Br. 2002;  27 270-273
• 18 Murrell G A, Francis M J, Bromley L. Free radicals and Dupuytren’s contracture.  Br Med J (Clin Res Ed). 1987;  295 1373-1375
• 19 Murrell G AC, Francis M JO. Free Radicals, Fibroblasts and Cell Proliferation. In: Rice-Evans C, (ed) Free Radicals, Diseased States and Anti-Radical Interventions.. London: Richelieu Press; 1989
• 20 Murrell G A, Francis M J, Bromley L. The collagen changes of Dupuytren’s contracture.  J Hand Surg Br. 1991;  16 263-266
• 21 Paoletti S. Faszien. München: Urban & Fischer; 2001
• 22 Perlemuter G, Davit-Spraul A, Cosson C et al. Increase in liver antioxidant enzyme activity in non-alcoholic fatty liver disease.  Liver Int. 2005;  25 946-953
• 23 Satish L, LaFramboise W A, O’Gorman D B et al. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren’s contracture. BMC Medical Genomics; 2008 http://www.biomedcentral.com/1755-8794/1/10
• 24 Singer I I, Kawka D W, Kazakis D M et al. In Vivo Co-Distribution of Fibronectin and Actin Fibers in Granulation Tissue: Immunofluorescence and Electron Microscope Study of the Fibronexus at the Myofibroblast Surface.  J Cell Biology. 1984;  98 2091-2106
• 25 Ulrich D, Ulrich F, Piatkowski A et al. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease.  Arch Orthop Trauma Surg. 2009;  129 1453-1459
• 26 Wipff P J, Rifkin D B, Meister J J et al. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix.  J Cell Biology. 2007;  179 1311-1323